1. Home
  2. SRRK vs CVCO Comparison

SRRK vs CVCO Comparison

Compare SRRK & CVCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SRRK
  • CVCO
  • Stock Information
  • Founded
  • SRRK 2012
  • CVCO 1965
  • Country
  • SRRK United States
  • CVCO United States
  • Employees
  • SRRK N/A
  • CVCO N/A
  • Industry
  • SRRK Biotechnology: Biological Products (No Diagnostic Substances)
  • CVCO Homebuilding
  • Sector
  • SRRK Health Care
  • CVCO Consumer Discretionary
  • Exchange
  • SRRK Nasdaq
  • CVCO Nasdaq
  • Market Cap
  • SRRK 4.2B
  • CVCO 3.8B
  • IPO Year
  • SRRK 2018
  • CVCO N/A
  • Fundamental
  • Price
  • SRRK $37.70
  • CVCO $520.73
  • Analyst Decision
  • SRRK Strong Buy
  • CVCO Buy
  • Analyst Count
  • SRRK 7
  • CVCO 2
  • Target Price
  • SRRK $40.43
  • CVCO $487.50
  • AVG Volume (30 Days)
  • SRRK 793.4K
  • CVCO 61.4K
  • Earning Date
  • SRRK 02-27-2025
  • CVCO 01-30-2025
  • Dividend Yield
  • SRRK N/A
  • CVCO N/A
  • EPS Growth
  • SRRK N/A
  • CVCO 2.67
  • EPS
  • SRRK N/A
  • CVCO 20.25
  • Revenue
  • SRRK N/A
  • CVCO $1,927,218,000.00
  • Revenue This Year
  • SRRK N/A
  • CVCO $14.00
  • Revenue Next Year
  • SRRK N/A
  • CVCO $8.80
  • P/E Ratio
  • SRRK N/A
  • CVCO $25.72
  • Revenue Growth
  • SRRK N/A
  • CVCO 4.11
  • 52 Week Low
  • SRRK $6.76
  • CVCO $331.08
  • 52 Week High
  • SRRK $46.98
  • CVCO $544.08
  • Technical
  • Relative Strength Index (RSI)
  • SRRK 41.93
  • CVCO 57.20
  • Support Level
  • SRRK $35.35
  • CVCO $514.87
  • Resistance Level
  • SRRK $38.61
  • CVCO $536.95
  • Average True Range (ATR)
  • SRRK 1.80
  • CVCO 13.71
  • MACD
  • SRRK -0.16
  • CVCO -0.99
  • Stochastic Oscillator
  • SRRK 34.20
  • CVCO 45.53

About SRRK Scholar Rock Holding Corporation

Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.

About CVCO Cavco Industries Inc. When Issued

Cavco Industries Inc designs and produces factory-built homes under the Cavco Homes, Fleetwood Homes, and Palm Harbor Homes brands. It also produces modular homes, park model homes, and vacation cabins, as well as commercial structures, among others. The company operates principally in two segments: Factory-built housing, which includes wholesale and retail systems-built housing operations, and the Financial services segment, which includes manufactured housing consumer finance and insurance. Cavco receives a majority of its revenue from the Factory-built housing segment.

Share on Social Networks: